Raymond James Financial Services Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Raymond James Financial Services Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-13,500	Closed	-$9K	–	2569
2017 Q2	$9K	Hold	13,500	–	–	﹤0.01%	2502
2017 Q1	$8K	Sell	13,500 -9,800	-42%	-$872K	﹤0.01%	2417
2016 Q4	$88K	Buy	23,300 +600	+3%	+$51.6K	﹤0.01%	2203
2016 Q3	$32K	Buy	22,700 +400	+2%	+$37.7K	﹤0.01%	2225
2016 Q2	$64K	Buy	22,300 +10,600	+91%	+$901K	﹤0.01%	2152
2016 Q1	$54K	Buy	+11,700	New	+$952K	﹤0.01%	1957

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Raymond James Financial Services Advisors's BMRN Position: Q3 2024 in Review

Raymond James Financial Services Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 5.1% in Q3 2024, buying an estimated $28.1K and bringing the position to 6,864 shares worth $482K. The position accounts for ﹤0.01% of the portfolio, ranked #2647.

Raymond James Financial Services Advisors first reported a position in BMRN in Q1 2016 and has held it in 31 quarters since. The position peaked at $2.23M in Q1 2023. 554 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

Raymond James Financial Services Advisors held 6,864 shares of BioMarin Pharmaceuticals worth $482K as of Q3 2024.
Raymond James Financial Services Advisors bought 336 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $28.1K.
BioMarin Pharmaceuticals made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #2647 holding.
Raymond James Financial Services Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2016 and has held it in 31 quarters since.
Raymond James Financial Services Advisors's BioMarin Pharmaceuticals position peaked at $2.23M in Q1 2023.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.